Annovis Bio, Inc.

Annovis Bio, Inc. announced full enrollment of its pivotal Phase 3 trial evaluating buntanetap in patients with early Alzheimer's disease (AD). The trial successfully enrolled 850 patients with pTau217-confirmed AD pathology across 83 clinical sites in the US, exceeding original projections. The company anticipates a 6-month symptomatic data readout in Q1 2027 and an 18-month disease-modifying data readout in Q1 2028, with preparations underway for two separate NDA submissions to the FDA.

Annovis Bio, Inc. announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer. Dr. Fang, who previously served as Senior Vice President, Research and Development, will now lead scientific strategy and research operations for the company's Alzheimer's disease (AD) and Parkinson's disease (PD) programs. This promotion comes as Annovis advances its lead drug candidate, buntanetap, toward top-line data readout from its pivotal Phase 3 AD study and a subsequent New Drug Application (NDA) submission.

Annovis Bio, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 17, 2026, where all five proposals submitted to stockholders were approved. A total of 62.65% of the company's common stock was represented at the meeting. Key approvals included the election of five directors, the ratification of Ernst & Young LLP as independent auditors, and an amendment to the 2019 Equity Incentive Plan to increase the number of shares available for issuance.

Annovis Bio, Inc. announced the pricing of a public offering, issuing 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 shares. The combined offering price for each share and nine-tenths of a warrant is $1.90, expected to generate approximately $15 million in gross proceeds. The company intends to use the net proceeds to advance the clinical development of its lead compound, Buntanetap, for Alzheimer's and Parkinson's diseases, and for general corporate purposes. The offering is anticipated to close around May 21, 2026.

Annovis Bio, Inc. announced a proposed underwritten public offering of its common stock and accompanying warrants. The shares and warrants will be offered together, with Canaccord Genuity serving as the sole bookrunner. The company intends to use the net proceeds to fund the continued Phase 3 clinical development of its lead compound, buntanetap, for Alzheimer's disease, as well as for working capital and general corporate purposes.

Annovis Bio reported a significant increase in net loss for Q1 2026, reaching $(17.6) million, compared to $(5.5) million in Q1 2025, primarily driven by a 233% surge in research and development expenses. The company's cash and cash equivalents decreased to $14.2 million, and management expressed substantial doubt about its ability to continue as a going concern. Additionally, Annovis Bio incurred severance expense related to the departure of its Chief Financial Officer in March 2026.

Annovis Bio reported strong progress in its clinical programs for Q1 2026, with 85% enrollment in its Phase 3 Alzheimer's disease (AD) trial and 40% enrollment in its Parkinson's disease (PD) open-label extension study. The company anticipates filing a New Drug Application (NDA) for symptomatic AD in early 2027 and for disease-modifying AD in early 2028. Financially, Annovis Bio reported a net loss per share of $(0.63) for the quarter, with research and development expenses increasing to $16.7 million.

Annovis Bio provided business updates and Q1 2026 financial results, highlighting significant progress in its clinical programs. The Phase 3 Alzheimer's disease (AD) trial is 85% enrolled and on track for full enrollment by summer 2026, with NDA submissions for symptomatic and disease-modifying AD expected in early 2027 and early 2028, respectively. The Parkinson's disease (PD) open-label extension study is 40% enrolled, targeting full enrollment by Q4 2026. The company reported cash and equivalents of $14.2 million as of March 31, 2026, and a net loss per share of $(0.63) for the quarter.

Annovis Bio, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026, with April 28, 2026, as the record date. Shareholders will vote on the election of five director nominees, the ratification of Ernst & Young LLP as the independent auditor, and an amendment to the 2019 Equity Incentive Plan. Additionally, there will be advisory votes on executive compensation and the frequency of such votes, with the Board recommending every two years. The Board unanimously recommends voting "FOR" all proposals.

Annovis Bio, Inc. announced the closing of an underwritten public offering, raising approximately $10 million in gross proceeds. This financing, combined with existing cash and a $1.5 million investment from the Board Chair, extends the company's cash runway through Q2 2027. The funding is critical as it fully supports operations through the anticipated Q1 2027 6-month symptomatic data readout from its Phase 3 Alzheimer's disease trial, which is 75% enrolled, and the subsequent New Drug Application (NDA) submission for buntanetap. The company is also advancing an open-label Parkinson's disease study, which has enrolled 28% of participants, and is preparing for regulatory efficiency with the FDA agreeing to integrate safety data from both AD and PD populations for the AD NDA.